Abcuro, Inc

Abcuro, Inc is a clinical stage biotechnology company founded in 2015 that focuses on developing immunotherapies for autoimmune diseases and cancer. The company is known for its flagship products ABC008 and ABC015, both of which target cytotoxic T and NK cells expressing the inhibitory immune checkpoint receptor KLRG1. ABC008, a first-in-class anti-KLRG1 antibody, aims to deplete cytotoxic T cells attacking healthy muscle tissue in patients with inclusion body myositis (IBM), a progressive and debilitating inflammatory skeletal muscle condition with no available pharmaceutical therapies. The noteworthy achievement is obtaining FDA orphan drug designation for ABC008 in IBM. On the other hand, ABC015, the company's anti-KLRG1 blocking antibody, is designed to reactivate inhibited cytotoxic T and NK cells in the tumor microenvironment. This holds significant promise in the realm of cancer treatment and underscores Abcuro's potential in addressing unmet medical needs. The most recent development for Abcuro, Inc is the $155.00M Series B investment which was secured on 17 August 2023. The investment involved notable backers such as Pontifax, RA Capital Management, BlackRock, Redmile Group, Samsara BioCapital, Sanofi Ventures, Soleus Capital, Mass General Brigham Ventures, Eurofarma, and Bain Capital Life Sciences. Abcuro's dedication to advancing treatments for autoimmune and cancer indications, coupled with its strategic partnerships and significant funding, positions the company as a compelling player in the biotechnology and healthcare industries.